Congratulations to Christine Sorenson, PhD, who was recently awarded an R01 grant from the National Institutes of Health/National Eye Institute (NIH/NEI) for her project titled “VEGF Antagonism and Resistance to Neovascular AMD.” This four-year, $1.5 million award will allow Dr. Sorenson, along with Co-Investigators from the UW Department of Ophthalmology & Visual Sciences, Barbara Blodi, MD and Nader Sheibani, PhD, to continue their research into vascular endothelial growth factor (VEGF), the key factor that drives neovascularization associated with neovascular age-related macular degeneration (nAMD), with anti-VEGF therapy being the standard treatment. The innovation of this proposal lies in their ability to determine whether genetic variation in Bim impacts the efficacy of anti-VEGF, the primary treatment modality for nAMD.